

Hyperparathyroidism Secondary

[View the current Hyperparathyroidism Secondary InDepth page on BioPortfolio.com \(PDF\)](#)
(http://www.bioportfolio.com/indepth/Hyperparathyroidism_Secondary.html) - Regularly Updated.

Recent Publications on Hyperparathyroidism Secondary:



- [Physiology and pathophysiology of the calcium-sensing receptor in the kidney.](#)
*The extracellular calcium-sensing receptor (CaSR) plays a major role in...*20th November, 2009
Cardiff University.- *Am J Physiol Renal Physiol.* 2009 Nov 18. ([DOI Direct Link](#))
- [Treatment of secondary hyperparathyroidism in haemodialysis patients: a randomised clinical trial comparing paricalcitol and alfacalcidol.](#)
*BACKGROUND: Secondary hyperparathyroidism is a common feature in patients...*13th November, 2009
Medical Department, Roskilde Hospital, Koegevej 7-13, DK-4000 Roskilde,- *BMC Nephrol.* 2009 Sep 24;10:28. ([DOI Direct Link](#))
- [Management of co-morbid diseases in a patient with established renal failure.](#)
*This follows on from an article relating to chronic kidney disease (CKD)...*30th October, 2009
- *J Ren Care.* 2009 Sep;35(3):151-8. ([DOI Direct Link](#))
- [Aggressive control of secondary hyperparathyroidism can result in immediate efficient blood pressure control in dialysis patients.](#)
*This follows on from an article relating to chronic kidney disease (CKD)...*29th October, 2009
Dialysis Unit, Veliki Clinic, Katerini, Greece.- *Nephrology (Carlton).* 2009 Aug;14(5):535-6. ([DOI Direct Link](#))
- [The clinical significance of parathyroid tissue calcium sensing receptor gene polymorphisms and expression levels in end-stage renal disease patients.](#)
*BACKGROUND: The calcium sensing receptor (CaSR) allows parathyroid and...*29th October, 2009
Departments of Molecular Genetics, Haydarpasa Numune Research and Training- *Clin Nephrol.* 2009 Aug;72(2):114-21.
- [Lack of evidence for administering vitamin D analogs to kidney failure patients to improve survivability.](#)
*INTRODUCTION: The Kidney Disease Outcome Quality Initiative (K/DOQI) Bone...*29th October, 2009
Scantibodies Laboratory, Inc., Santee, CA 92071, USA.- *Clin Nephrol.* 2009 Aug;72(2):97-104.
- [Middle-term use of Cinacalcet in paediatric dialysis patients.](#)
*The effects of the calcimimetic drug Cinacalcet were assessed in six...*20th October, 2009
Children's Renal Unit, Bristol Royal Hospital for Children, Upper Maudlin- *Pediatr Nephrol.* 2009 Oct 17. ([DOI Direct Link](#))
- [Postoperative hypocalcemia after parathyroidectomy for renal hyperparathyroidism in the era of cinacalcet.](#)
*Chronic kidney disease is often accompanied by hyperparathyroidism....*10th October, 2009
Department of Surgery, University of North Carolina School of Medicine at- *Am Surg.* 2009

- Sep;75(9):843-7.
- [Indirect regulation of PTH by estrogens may require FGF23.](#)
*The mechanisms by which estrogens modulate PTH are controversial...*3rd October, 2009
Bone and Mineral Research Unit, Instituto Reina Sofia de Investigacion,- J Am Soc Nephrol. 2009
Sep;20(9):2009-17. Epub 2009 Jul 23. ([DOI Direct Link](#))
 - [\[Recurring secondary hyperparathyroidism: case report\]](#)
*The authors report a rare case of persistently recurring secondary...*25th September, 2009
- Klin Med (Mosk). 2009;87(7):67-70.
 - [Emerging topics in pediatric bone and mineral disorders 2008.](#)
*The calcium sensing receptor (CaSR) and fibroblast growth factor 23...*23rd September, 2009
Department of Pediatrics, Levine Children's Hospital at Carolinas Medical- Semin Nephrol. 2009
Jul;29(4):370-8. ([DOI Direct Link](#))
 - [Are vitamin D receptor activators useful for the treatment of thrombosis?](#)
*Vitamin D3 is produced in the skin and modified in the liver and kidneys...*26th August, 2009
University of Illinois at Chicago, Department of Pharmacy Practice, 833- Curr Opin Investig Drugs.
2009 Sep;10(9):919-27.
 - [Two hundred and two consecutive operations for secondary hyperparathyroidism: has medical management changed the profiles of patients requiring parathyroidectomy?](#)
*BACKGROUND: Because of improvements in the medical management of end-stage...*19th August, 2009
Department of Surgery, University of California, San Francisco, CA 94115,- Surgery. 2009
Aug;146(2):296-9. Epub 2009 Jun 26. ([DOI Direct Link](#))
 - [Hyperparathyroidism.](#)
*Hyperparathyroidism is due to increased activity of the parathyroid...*1st August, 2009
Unit of Clinical Chemistry, School of Clinical Sciences, University of- Lancet. 2009 Jul
11;374(9684):145-58. ([DOI Direct Link](#))
 - [Effects of calcimimetic on vascular calcification and atherosclerosis in uremic mice.](#)
*Recent in vitro and in vivo studies suggest that the calcium-sensing...*24th March, 2009
Inserm Unit 845, Necker Hospital, University Paris 5, Paris, France.- Bone. 2009 Jul;45 Suppl 1:S30-4.
Epub 2009 Mar 19. ([DOI Direct Link](#))

BioNews Results for Hyperparathyroidism Secondary

- [Secondary Hyperparathyroidism: Pathophysiology and Treatment](#)
Medscape: Nov 10 2009 11:53PM Matching: hyperparathyroidism secondary
- [Persistent Secondary Hyperparathyroidism and Vertebral Fractures in Kidney Transplantation: Role of Calcium-Sensing Receptor Polymorphisms and Vitamin D Deficiency](#)
MDLinx: Oct 28 2009 12:54PM Matching: hyperparathyroidism secondary

Hyperparathyroidism Secondary Patents:



- 7582658- [Bicyclic compound](#)
- 6310226- [Vitamin D analogues](#)
- 6197982- [Vitamin D analogues](#)
- 5994332- [Vitamin D analogues](#)
- 5932565- [Vitamin D analogues](#)
- 5861386- [Method for treating and preventing secondary hyperparathyroidism](#)
- 5753633- [Method of inhibiting bone resorption](#)
- 5716945- [Vitamin D analogues](#)
- 5710142- [Vitamin D analogues](#)
- 5707980- [Method for treating and preventing secondary hyperparathyroidism](#)
- 5612325- [Vitamin D analogues having a halogen-or azido- substituted side chain](#)
- 5602116- [Method for treating and preventing secondary hyperparathyroidism](#)
- 5589471- [Vitamin D analogues containing a hydroxy or alkylated hydroxy group in the 20-position](#)
- 5554599- [22-thio vitamin D derivatives](#)
- 5545633- [17-ene vitamine D analogues](#)
- 5447924- [Vitamin D analogues](#)
- 5446034- [Vitamin D analogues](#)
- 5063221- [Treatment for hyperparathyroidism with use of vitamin D derivatives](#)
- 6376479- [Method for treating and preventing hyperparathyroidism](#)
- 6399797- [Vitamin D analogues](#)
- 6537980- [Vitamin D analogues and their pharmaceutical use](#)
- 7531533- [6-Membered heterocyclic compound and use thereof](#)
- 7427662- [Inhibition of angiogenesis and destruction of angiogenic vessels by apolipoprotein A-I and high density lipoprotein](#)
- 7361789- [Dihydronaphthalene compounds, compositions, uses thereof, and methods for synthesis](#)
- 7318925- [Methods of use for antibodies against parathyroid hormone](#)
- 7288253- [Antibodies directed to parathyroid hormone \(PTH\) and uses thereof](#)
- 7232667- [Keratinocyte growth factor-2 polynucleotides](#)
- 7166585- [24-Sulfur-substituted analogs of 1.alpha.,25-dihydroxy vitamin D.sub.3](#)
- 7148211- [Formulation for lipophilic agents](#)
- 7101865- [24-sulfoximine vitamin D3 compounds](#)
- 7071178- [Use of vitamin D-derivatives in the treatment of osteoporosis and related bone disorders, as well as novel vitamin D3-derivatives](#)
- 6939895- [Calcium receptor-active compounds](#)
- 6750255- [Calcium receptor-active compounds](#)
- 6743590- [Methods for differentiating and monitoring parathyroid and bone status related diseases](#)
- 6693077- [Keratinocyte growth factor-2](#)
- 6689566- [Methods, kits, and antibodies for detecting parathyroid hormone](#)
- 6646143- [Vitamin D analogues](#)
- 6573255- [Vitamin D analogues](#)
- 4948789- [Suppression of parathyroid hormone synthesis and secretion](#)

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:
Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road,
Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

